top of page
Executive Spotlights

Sanofi Forges $740M Partnership with Belharra to Pioneer Small Molecule Treatments for Immunological Diseases

San Mateo, CA and San Diego, June 18, 2024 (Globe Newswire) -- Belharra Therapeutics and Sanofi have partnered to discover novel small molecule therapies for immunological diseases using Belharra’s chemoproteomics platform. Sanofi will manage the preclinical, clinical, and commercial stages, with Belharra potentially earning nearly $740 million in milestone payments and royalties. This strategic collaboration aims to leverage Belharra’s cutting-edge technology to advance Sanofi’s pipeline of immunology treatments.


Read full article here.

Recent Posts

See All

Radiant Vision Systems Appoints new CEO

Redmond, WA, July 1, 2024 (Radiant) -- Radiant Vision Systems has appointed Stone Jiang as their new CEO, succeeding Doug Kreysar who is retiring. Jiang, previously the Executive Vice President and

Orion and Merck Secure $1.63B Agreement

Rahway, NJ, July 1, 2024 (Business Wire) -- Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, and Orion Corporation ("Orion") have agreed to convert their co-development and co-commercial

コメント


Life Science Headlines
bottom of page